Established in Jerusalem in 1901, today they are the world's largest producer of generic pharmaceuticals. Acquired Actavis Generics from Allergan in 2016 for US$40.5 billion.
|Teva Pharmaceutical Industries Ltd||ISR||website|
|Teva Pharmaceutical Industries Ltd|
In 2019, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of B.
[Source 2019][More on Climate Change]
This company received a score of 35.9/100 in the Newsweek Green Rankings 2016, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
[Source 2016][More on Sustainability Reporting]
In 2016 this company agreed to pay more than $519 million to settle US criminal and civil allegations that the company bribed officials in Mexico, Russia and Ukraine to gain business for its medications.
[Source 2016][More on Finance]
This company received an S&P Global ESG Score of 33/100 in the Pharmaceuticals category of the 2019 SAM Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices. The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
[Source 2019][More on Sustainability Reporting]
A 2015 report by Sum Of Us reveals that the largest pharmaceutical corporations are complicit in fuelling one of the most serious public health crises facing society today. Pharmaceutical companies, including this one, are sourcing active pharmaceutical ingredients (APIs) from companies in China which are responsible for massive environmental pollution from its antibiotic factories. Teva has links with at least three of the Chinese companies identified in the report, all of which have been in the Chinese media spotlight for various offences including improper waste management and the release of noxious chemicals.
[Source 2015][More on Habitats]
In 2015 this company agreed to pay US$1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. The settlement stems from charges brought in 2008 against Cephalon Inc, which was acquired by Teva in 2012.
[Source 2015][More on Finance]
|Company Structure||Public company|
|Revenue||US$22 billion in 2017|
|# Employees||51,792 in 2017|
|Subsidiaries||Teva Pharma Australia Pty Ltd|
|Address||Petah Tikva, Israel|